Dilated Cardiomyopathy in Dogs: Welfare Management of a Serious Heart Disease

Canine dilated cardiomyopathy (DCM) is a progressive disease of the heart muscle causing reduced cardiac output and eventually heart failure. Breed predisposition, dietary links, and genetic factors all influence who develops DCM and how it progresses.

Key Facts

DCM involves dilation and weakening of the left ventricle, impairing the heart's ability to pump blood effectively; it is the second most common cardiac disease in dogs.
Giant and large breeds are most affected: Doberman Pinschers, Great Danes, Boxers, Irish Wolfhounds, and Cocker Spaniels have the highest prevalence.
Dobermans are uniquely affected: occult (preclinical) DCM is present in approximately 40-50% of the breed; 24-hour Holter monitoring and echocardiography are recommended for breeding dogs.
A link between grain-free diets (high in legumes) and DCM was identified by the FDA in 2018-2022; the mechanism remains under investigation but some taurine-deficient cases resolved with diet change.
Clinical signs develop as the disease progresses: exercise intolerance, coughing, laboured breathing, weakness, and syncope (fainting).
Atrial fibrillation (AF) is a common arrhythmia complication; sudden death from ventricular arrhythmia is a significant risk in Dobermans with occult DCM.
Pimobendan is the cornerstone of treatment, improving cardiac contractility and reducing preload; it significantly extends the asymptomatic phase when started early.
ACE inhibitors, diuretics, and anti-arrhythmic drugs are added as disease progresses; combination therapy can extend good-quality life by months to years.

Welfare Considerations

Dogs with DCM experience a progressive deterioration in quality of life that must be carefully managed. During the occult (preclinical) phase, dogs may appear normal while the disease silently progresses; early detection through breed-appropriate screening enables treatment that delays the onset of clinical signs. Once congestive heart failure develops, dogs experience breathlessness, fatigue, and reduced capacity for the activities they value most — exercise, play, and interaction. Welfare management requires: optimising pharmacological treatment to minimise fluid accumulation and maximise cardiac output, monitoring for arrhythmia, and regularly assessing quality of life. Sudden cardiac death — particularly in Dobermans — is a welfare concern that may be partially mitigated by anti-arrhythmic therapy in high-risk individuals. End-of-life decisions should anticipate and precede respiratory distress.

What You Can Do

If you own a DCM-predisposed breed, ask your vet about regular cardiac screening including echocardiography and Holter monitoring.
Discuss pimobendan with your vet if your dog has been diagnosed with occult DCM — early treatment extends the asymptomatic period significantly.
Avoid grain-free or legume-heavy diets unless specifically indicated; choose WSAVA-compliant commercial diets from established manufacturers.
Monitor your dog daily for signs of decompensation: increased resting respiratory rate, coughing, or reduced exercise tolerance.
Create an emergency protocol with your vet for acute heart failure episodes, including what signs warrant emergency care and what medications to have at home.